Anixa biosciences stock.

Market Capitalization. $100.05 million. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $10.50. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest Social Media.22 Mar 2021 ... Anixa Biosciences, Inc. is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.Anixa Biosciences, Inc. announced that, in partnership with Moffitt Cancer Center, it has completed treatment of the first patient cohort in the ongoing clinical trial of …Anixa Biosciences - ANIX - Stock Price Today - Zacks Anixa Biosciences (ANIX) (Delayed Data from NSDQ) $3.34 USD +0.03 (0.91%) Updated Nov 30, 2023 04:00 PM ET After-Market: $3.34 0.00...

Nov 27, 2023 · Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic ...18 Okt 2023 ... Anixa Biosciences; A Brief Investor Q&A With CEO and Chairman Amit Kumar, PhD. 3 views · 5 minutes ago ...more ...

Nov 30, 2023 · View ANIXA BIOSCIENCES INC ANIX investment & stock information. Get the latest ANIXA BIOSCIENCES INC ANIX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Anixa Biosciences (Nasdaq:ANIX) - Stock Price, News & Analysis - Simply Wall St Stocks / Pharmaceuticals & Biotech Anixa Biosciences NasdaqCM:ANIX …Firm. Analyst. Chardan. Matthew Barcus, Ph.D. H.C. Wainwright & Co. Yi Chen, Ph.D. Raghuram Selvaraju, Ph.D. Anixa Biosciences, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Anixa Biosciences, Inc.'s performance made by these analysts are theirs alone and do not represent …What Makes ANIXA BIOSCIENCES INC (ANIX) a New Buy Stock (Zacks) May-22-23 08:30AM Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire) Apr-25-23 09:40AM ... Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that …

About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 ...

Currently, the analyst consensus on Anixa Biosciences is a Moderate Buy with an average price target of $12.00. See today’s best-performing stocks on TipRanks >> ANIX market cap is currently ...

ANIXA BIOSCIENCES INC (ANIX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is…Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt ...Anixa Biosciences, Inc. announced that, in partnership with Moffitt Cancer Center, it has completed treatment of the first patient cohort in the ongoing clinical trial of …Nov 24, 2023 · Anixa Biosciences (ANIX) Quote Overview ... A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its annual earnings. In general, a lower number or multiple is usually ... Anixa Biosciences (Nasdaq:ANIX) - Stock Price, News & Analysis - Simply Wall St Stocks / Pharmaceuticals & Biotech Anixa Biosciences NasdaqCM:ANIX …Dec 1, 2023 · Anixa Biosciences Stock Price, News & Analysis (NASDAQ:ANIX) $3.27 -0.07 (-2.10%) (As of 12/1/2023 ET) Compare Today's Range $3.25 $3.43 50-Day Range $2.85 $3.64 52-Week Range $2.75 $6.45 Volume 45,375 shs Average Volume 70,005 shs Market Capitalization $101.60 million P/E Ratio N/A Dividend Yield N/A Price Target $10.50 SAN JOSE, Calif., April 28, 2022 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt ...Anixa Biosciences Inc stock performance at a glance. Check Anixa Biosciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its …When Anixa Biosciences last reported its balance sheet in January 2023, it had zero debt and cash worth US$28m. Importantly, its cash burn was US$7.3m over the trailing twelve months. So it had a ...Complete Anixa Biosciences Inc. stock information by Barron's. View real-time ANIX stock price and news, along with industry-best analysis.SAN JOSE, Calif., April 28, 2022 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) Annual …Anixa Biosciences Inc: Overview. Anixa Biosciences Inc (Anixa) is a biotechnology company. The company develops and acquires patented technologies in the areas such as cancer diagnostics, encrypted communications and semiconductor fabrication. It also develops non-invasive blood tests for the early detection of solid tumor-based cancers.

Discover historical prices for ANIX stock on Yahoo Finance. View daily, weekly or monthly format back to when Anixa Biosciences, Inc. stock was issued. Anixa Biosciences Stock Price, News & Analysis (NASDAQ:ANIX) $3.27 -0.07 (-2.10%) (As of 12/1/2023 ET) Compare Today's Range $3.25 $3.43 50-Day Range $2.85 $3.64 52-Week Range $2.75 $6.45 Volume 45,375 shs Average Volume 70,005 shs Market Capitalization $101.60 million P/E Ratio N/A Dividend Yield N/A Price Target $10.50

About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a …Oct 23, 2023. Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardFind the latest Anixa Biosciences, Inc. (ANIX) stock quote, history, news and other vital information to help you with your stock trading and investing.SAN JOSE, Calif., May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in ...H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) today and set a price target of $11.00. The company’s shares closed yesterday at $4.21.Anixa Biosciences Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for ANIX stock stock is $10.5, which predicts an increase of 258.36%. The lowest target is $9.00 and the highest is $12. On average, analysts rate ANIX stock stock as a strong buy.Nov 28, 2023 · In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $12.00. Yi Chen has given Anixa Biosciences ... Anixa Biosciences Inc. company facts, information and financial ratios from MarketWatch. ... 9:34a Target stock price target raised to $160 from $135 at BofA SecuritiesApr 28, 2022 · SAN JOSE, Calif., April 28, 2022 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...

Get Anixa Biosciences Inc (ANIX.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

14 Agu 2023 ... SAN JOSE, Calif., Aug. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company ...

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial. SAN JOSE, Calif. , May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in conjunction ... 6 months ago - PRNewsWire.Apr 28, 2022 · SAN JOSE, Calif., April 28, 2022 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ... The estimated net worth of Amit Kumar is at least $1.51 million as of July 31st, 2023. Dr. Kumar owns 461,925 shares of Anixa Biosciences stock worth more than $1,510,495 as of October 18th. This net worth approximation does not reflect any other investments that Dr. Kumar may own. Additionally, Dr. Kumar receives an annual salary …A price increase of 27.5% over the past four weeks ensures that the trend is still in place for the stock of this company. Moreover, ANIX is currently trading at 85.6% of its 52-week High-Low ...SAN JOSE, Calif., Aug. 15, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer and infectious diseases ...Oct 13, 2023 · The cell therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T therapy in that it targets the FSHR, which research indicates is exclusively expressed on ovarian cells in healthy adult females. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.8 hari yang lalu ... SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company ...

Nov 24, 2023 · Anixa Biosciences (ANIX) Quote Overview ... A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its annual earnings. In general, a lower number or multiple is usually ... SAN JOSE - Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 - 3, 2023.Anixa Biosciences, Inc. company earnings calendar and analyst expectations - Upcoming and past events | BOERSE MUENCHEN: CY71 | BOERSE MUENCHENInstagram:https://instagram. willscot mobile minibest financial magazinekuiper stock symbolonline futures trading courses The estimated net worth of Amit Kumar is at least $1.51 million as of July 31st, 2023. Dr. Kumar owns 461,925 shares of Anixa Biosciences stock worth more than $1,510,495 as of October 18th. This net worth approximation does not reflect any other investments that Dr. Kumar may own. Additionally, Dr. Kumar receives an annual salary …Nov 28, 2023 · In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $12.00. Yi Chen has given Anixa Biosciences ... voya financialswho owns truly beverage Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others. rtx stock news Anixa Biosciences Inc’s trailing 12-month revenue is $0.2 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-0.320 per share for the current fiscal year. Anixa Biosciences Inc does not currently pay a dividend.Anixa Biosciences (ANIX) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences, with a price target of $12.00 . The company’s shares closed last ...